Journal article
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death
SE Birch, JG Kench, E Takano, P Chan, AL Chan, K Chiam, AS Veillard, P Stricker, S Haupt, Y Haupt, L Horvath, SB Fox
Annals of Oncology | OXFORD UNIV PRESS | Published : 2014
Abstract
Background: The promyelocytic leukemia (PML) tumor suppressor plays an important role in the response to a variety of cellular stressors and its expression is downregulated or lost in a range of human tumors. We have previously shown that the E3 ligase E6-associated protein (E6AP) is an important regulator of PML protein stability but the relationship and clinical impact of PML and E6AP expression in prostatic carcinoma is unknown. Methods: E6AP and PML expression was assessed in tissue microarrays from a phase I discovery cohort of 170 patients treated by radical prostatectomy for localized prostate cancer (PC). Correlation analysis was carried out between PML and E6AP expression and clinic..
View full abstractGrants
Awarded by Prostate Cancer Foundation of Australia
Funding Acknowledgements
This work was supported by the Prostate Cancer Foundation of Australia (YH, NHMRC SRF #628426), the Victorian Cancer Agency (YH, CAPTIV), National Health and Medical Research Council Program Grant (ID 535903) and Cancer Institute NSW Program Grant (10/TPG/1-04).